The stock of the vaccine-specialized company is trading at €4.17 at midday, down 4.1% from Friday's close. This decline is part of a broader correction over the past week, with a cumulative loss of 7.87%. Trading volumes remain limited, representing 0.26% of the capital, a moderate level that reflects some restraint from market participants. Over a longer period, the stock still maintains significant gains, with an increase of 52.67% over three months and 56.69% over a year, significantly outperforming the CAC 40's +7.36% over twelve months. The Paris index remains almost stable this Monday, with a slight decrease of 0.01%.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
This consolidation phase comes two weeks after a series of major announcements on October 6. The company then revised its sales forecasts for 2025 downwards, now expected between €155 and €170 million versus the previous €170 to €180 million, due to the suspension by the US FDA of its chikungunya vaccine license. At the same time, Valneva announced a delay to the first half of 2026 for the results of the Phase III trial of its Lyme disease vaccine, originally expected at the end of October. The company also refinanced its debt with a new $500 million loan from Pharmakon Advisors, improving its financial structure with a maturity extended to the end of 2030. No specific news was released this Monday to explain the day's movement.
Technically, the stock is trading below its 50-day moving average, which is at €4.31, reflecting short-term downward pressure. However, it remains well above its 200-day moving average, positioned at €3.27, confirming a fundamental upward trend. The Chaikin Money Flow, which measures the intensity of buyer and seller flows, shows a negative value of -0.06, suggesting a dominance of capital outflows over inflows. This indication is corroborated by a negative On-Balance Volume, a sign of recent selling accumulation. With a monthly volatility of 16.78% and a beta of 0.62, the stock exhibits movement amplitudes above the market average, while maintaining moderate sensitivity to fluctuations in the benchmark index. The Relative Strength Index (RSI) at 44 is in a neutral zone, without a clear buy or sell signal at this stage.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
